An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo

New England Journal of Medicine

Volumn 339, Issue 11, 1998, Pages 725-732

  Weissman, Neil J ^a   Tighe Jr , John F ^a   Gottdiener, John S ^a   Gwynne, John T ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; PLACEBO;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENANTIOMER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; OBESITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SUSTAINED RELEASE PREPARATION; VALVULAR HEART DISEASE;

ADULT; AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; FENFLURAMINE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; OBESITY; PREVALENCE; PULMONARY ARTERY;

EID: 0032505060     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199809103391103     Document Type: Article

References (21)

1. Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med Clin North Am 1989;73:111-38.
2. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998;338:1-7.
3. Weintraub M, Sundaresan PR, Cox C. Long-term weight control study. VI. Individual participant response patterns. Clin Pharmacol Ther 1992;51: 619-33.
4. Davis R, Faulds D. Dexfenfluramine - an updated review of its therapeutic use in the management of obesity. Drugs 1996;52:696-724.
5. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. [Erratum, N Engl J Med 1997;337:1783.]
6. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
7. FDA analysis of cardiac valvular dysfunction with use of appetite suppressants. Washington, D.C.: Food and Drug Administration, 1997. (See http://www.fba.gov/cder/news/slides/sld001.htm.) (Also available from NAPS [document no. 05472 for 16 pages], c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163-3513. This is not a multiarticle document. Remit in advance [in U.S. funds only] $15 for the first 20 photocopies [$0.50 per page thereafter] or $5 for the first microfiche [$1 per microfiche thereafter]. Outside the U.S. and Canada add postage of $4.50 for the first 20 pages, $1 for every 10 pages thereafter [$1 per microfiche]. There is a $25 invoicing fee for purchase orders.)
8. Kurz X, Van Erman A. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:1772-3.
9. Rasmussen S, Corya BC, Glassman RD. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:1773.
10. Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine. N Engl J Med 1997;337:636.
11. Helmcke F, Nanda NC, Hsiung MC, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 1987;75:175-83.
12. Perry GJ, Helmcke F, Nanda NC, Byard C, Soto B. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 1987; 9:952-9.
13. Ranganathan N, Lam JH, Wigle ED, Silver MD. Morphology of the human mitral valve. II. The valve leaflets. Circulation 1970;41:459-67.
14. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-62.
15. Singh JP, Evans JC, Levy D, Larson MG, Fuller DL, Lehman B. Prevalence of valvular regurgitation in a population-based cohort. Circulation 1997;96:Suppl I:I-541. abstract.
16. Choong CY, Abascal VM, Weyman J, et al. Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J 1989;117: 636-42.
17. Reid CL, Gardin JM, Yunis C, Kurosaki T, Flack JM. Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population: the CARDIA Study. Circulation 1994;90:Suppl I:I-282. abstract.
18. Jobic Y, Slama M, Tribouilloy C, et al. Doppler echocardiographic evaluation of valve regurgitation in healthy volunteers. Br Heart J 1992;69: 109-13.
19. Klein AL, Burstow DJ, Tajik AJ, et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990;3:54-63.
20. Wong J, Reddy SS, Klein AL. Anorectic drugs and valvular heart disease: a biological and clinical perspective. Cleve Clin J Med 1998;65:35-41.
21. Statement of the American College of Cardiology on recommendations for patients who have used anorectic drugs. Bethesda, Md.: American College of Cardiology, October 18, 1997. (See http:// www.acc.org/pubs/news/statement.html.) (Also available from NAPS [document no. 05472 for 3 pages], c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163-3513. This is not a multiarticle document. Remit in advance [in U.S. funds only] $15 for the first 20 photocopies [$0.50 per page thereafter] or $5 for the first microfiche [$1 per microfiche thereafter]. Outside the U.S. and Canada add postage of $4.50 for the first 20 pages, $1 for every 10 pages thereafter [$1 per microfiche]. There is a $25 invoicing fee for purchase orders.)